Welcome to the e-CCO Library!

DOP48 Gene expression landscape of epithelial monolayer in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Sæterstad1, A.E. Østvik2,3, A.K. Sandvik1,2,3, A. Granlund Van Beelen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. D’Haens*1, S. Danese2, M. Davies3, M. Watanabe4, T. Hibi5

Created: Friday, 22 February 2019, 9:41 AM
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof of concept study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Geert D'Haens
Created: Tuesday, 28 May 2019, 3:32 PM
S1P agonist
Files: 1
DOP48: Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futility
Year: 2024
Source: ECCO'24 Stockholm
Authors: Deleu, Sara
Created: Tuesday, 30 April 2024, 5:03 PM
DOP48: Gene expression landscape of epithelial monolayer in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Atle Granlund Van Beelen
Created: Tuesday, 23 June 2020, 5:40 PM
DOP48: Gene expression landscape of epithelial monolayer in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Atle Granlund Van Beelen
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP48: Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBD
Year: 2022
Source: ECCO'22
Authors: Hanna, J.(1);Beke, F.(2);O'Brien, L.(2);Kapeni, C.(2);Chen, H.C.(2);Carbonaro, V.(2);Kim, A.(3);Kishore, K.(2);Adolph, T.E.(4);Skjoedt, M.O.(5);Skjoedt, K.(6);de la Roche, M.(7);de la Roche, M.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP48: Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn's disease. The ENIGMA study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Teh, J.J.(1);Kang, S.(1);Leonard, A.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching , J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP48: Use of biologic therapies with different mechanisms of action (MOA) in the first-line (1L) treatment of Crohn’s Disease (CD) in the U.S.
Year: 2021
Source: ECCO'21 Virtual
Authors: Huang, Z.(1);Ba, Y.(1);Kamble, P.(1);Wang, S.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Douadi1, E. Vazeille1, C. Chambon2, M. Hébraud3, M. Dodel4, B. Pereira4, D. Coban4, A. Buisson4, N. Barnich1

Created: Thursday, 30 January 2020, 10:12 AM
DOP49: Context-dependent roles of High-mobility group box 1 (HMGB1) during intestinal inflammation and carcinogenesis
Year: 2022
Source: ECCO'22
Authors: Zierz, E.(1);Foelsch, K.(1);Pelczar, P.(1);Qi, M.(2);Alawi, M.(2);Clauditz, T.(3);Gagliani, N.(4);Huber, S.(1);Huebener, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP49: Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group
Year: 2021
Source: ECCO'21 Virtual
Authors: Pugliese, D.(1);Privitera, G.(2);Armuzzi, A.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

Created: Friday, 22 February 2019, 9:41 AM
DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Walter Reinisch
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis
Files: 1
DOP49: Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn's disease. The ENIGMA study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kang, S.(1);Teh, J.J.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching, J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP49: Quantitative proteomics analysis of macrophages from Crohn’s Disease patients and infected with adherent-invasive Escherichia coli
Year: 2020
Source: ECCO'20 Vienna
Authors: Anthony Buisson
Created: Tuesday, 23 June 2020, 5:40 PM
DOP49: Quantitative proteomics analysis of macrophages from Crohn’s Disease patients and infected with adherent-invasive Escherichia coli
Year: 2020
Source: ECCO'20 Vienna
Authors: Anthony Buisson
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1